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Distinct regulatory signaling mechanisms exist between cortisol and brain derived
neurotrophic factor (BDNF) that may influence secondary injury cascades associated
with traumatic brain injury (TBI) and predict outcome. We investigated concurrent CSF
BDNF and cortisol relationships in 117 patients sampled days 0–6 after severe TBI
while accounting for BDNF genetics and age. We also determined associations between
CSF BDNF and cortisol with 6-month mortality. BDNF variants, rs6265 and rs7124442,
were used to create a gene risk score (GRS) in reference to previously published
hypothesized risk for mortality in “younger patients” (<48 years) and hypothesized BDNF
production/secretion capacity with these variants. Group based trajectory analysis (TRAJ)
was used to create two cortisol groups (high and low trajectories). A Bayesian estimation
approach informed the mediation models. Results show CSF BDNF predicted patient
cortisol TRAJ group (P = 0.001). Also, GRS moderated BDNF associations with cortisol
TRAJ group. Additionally, cortisol TRAJ predicted 6-month mortality (P = 0.001). In
a mediation analysis, BDNF predicted mortality, with cortisol acting as the mediator
(P = 0.011), yielding a mediation percentage of 29.92%. Mediation effects increased
to 45.45% among younger patients. A BDNF*GRS interaction predicted mortality in
younger patients (P = 0.004). Thus, we conclude 6-month mortality after severe TBI
can be predicted through a mediation model with CSF cortisol and BDNF, suggesting a
regulatory role for cortisol with BDNF’s contribution to TBI pathophysiology and mortality,
particularly among younger individuals with severe TBI. Based on the literature, cortisol
modulated BDNF effects on mortality after TBI may be related to known hormone and
neurotrophin relationships to neurological injury severity and autonomic nervous system
imbalance.
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INTRODUCTION
Although death rates have decreased over time, ∼2.5 million
Americans experience traumatic brain injury (TBI) yearly, with
more than 50,000 associated fatalities (Centers for Disease
Control Prevention, 2016). TBI results in several acute secondary
injury cascades, that include aseptic inflammation (Kumar et al.,
2015, 2016), excitotoxicity (Wagner et al., 2005), monaminergic
dysfunction (Wagner et al., 2007), neurotrophin abnormalities
(Failla et al., 2016), and stress induced steroidogenesis (Wagner
et al., 2011a; Santarsieri et al., 2014) that result in blood
brain barrier disruption and CNS damage (Wagner et al.,
2011b; Goyal et al., 2013); representative biomarkers for each
of these pathways have been identified in CSF and serum
for clinical populations with moderate/severe TBI. However,
individual biomarker studies have limitations with predicting
therapeutic treatment response (Maas et al., 2010), which may
be due to the focus of current research on single biomarker
relationships, rather than the interactions of several. Further,
many clinical intervention studies have not included biomarker
characterization to assess treatment effects.
Under certain conditions glucocorticoids, cortisol in
humans and corticosterone in animals, can be neuroprotective,
anti-inflammatory, and anticonvulsive, in order to restore
homeostasis after injury, as the end product of the stress-
activated HPA axis (McEwan, 1999; Jeanneteau et al., 2008; Joëls,
2008). Based on this premise, the Corticosteroid Randomization
after Significant Head Injury (CRASH) trial administered the
glucocorticoid methylprednisolone acutely after TBI. This trial
was stopped prematurely when treatment had a higher mortality
rate than placebo (Roberts et al., 2004). Recent work suggests
elevated cortisol levels, when linked to prolonged stress, can
impair synaptic plasticity and can result in neuronal cell death
(Antonawich et al., 1999; Rothman and Mattson, 2013). Also,
our previous work shows endogenous CSF cortisol levels are
markedly increased after TBI, and we showed that sustained
elevations in CSF cortisol profiles are associated with poorer
outcomes (Santarsieri et al., 2014).
Brain derived neurotrophic factor (BDNF) is well-known
for its roles in neuronal survival, neuronal maintenance, and
neural plasticity. Despite these benefits, BDNF administration
after experimental TBI was not protective against structural or
functional deficits (Blaha et al., 2000). Subsequent work suggests
that BDNF effects on TBI pathophysiologymay be target receptor
dependent, with the pro-apoptotic p75 receptor upregulation
post-injury contributing to cell death (Rostami et al., 2014;
Sebastiani et al., 2015). Our previous clinical work suggests CSF
Abbreviations: BBB, blood brain barrier; BDNF, brain-derived neurotropic
factor; CREB, cAMP response element binding protein; ELISA, enzyme-linked
immunosorbent assay; GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale;
GRS, gene risk score; HPA axis, hypothamic-pituitary-adrenal axis; HRV, heart
rate variability; MAPK/ERK, microtubule associated protein kinase/extracellular
signal-regulated kinases; NT3, Neurotrophin-3; RCS, restricted cubic spline
analysis; RIA, radioimmunoassay; Shp2, Src Homology Phosphatase 2; SNP,
single nucleotide polymorphism; TBI, traumatic brain injury; TRAJ, group-based
trajectory analysis; TrkB, tropomyosin receptor kinase B.
BDNF levels are elevated after TBI and associated with earlier
time until death (Failla et al., 2016).
Brain derived neurotrophic factor (BDNF) and cortisol
regulation are interconnected via multiple mechanisms
(Rothman and Mattson, 2013), and levels of each are modified
under stress, which are relevant in the context of TBI, a major
pathophysiological stressor. While the exact pathways by which
cortisol and BDNF interact are not completely known, some
work shows glucocorticoid response elements are located in the
BDNF gene promoter region, suggesting transcriptional control
over BDNF production (Rothman and Mattson, 2013). Other
indirect mechanisms propose glucocorticoid regulation of BDNF
through CREB, MAPK/ERK, or Shp2 (Kumamaru et al., 2008,
2011; Alboni et al., 2011). BDNF, through synaptic modulation
in the nucleus of the solitary tract (Clark et al., 2011) and
hypothalamus (Tapia-Arancibia et al., 2004), may also regulate
HPA-axis reactivity and cortisol releasing hormone (Jeanneteau
et al., 2012). Interactive signaling between BDNF and cortisol
may significantly influence HPA-reactivity immediately after
TBI. The literature on regulatory effects between cortisol and
BDNF is sparse, yet one experimental TBI study, involving young
adult rats, does suggest that both injury and adrenalectomy
independently resulted in acute (within 4 h of injury) elevations
in hippocampal BDNF mRNA expression, and the effects of both
TBI and adrenalectomy on BDNF elevations are cumulative.
Alternatively, corticosterone replacement prevented this increase
among adrenalectomized rats (Grundy et al., 2000). Together,
these results suggest that cortisol can have acute modulatory
effects that limit increased BDNF expression after TBI. Similar
effects are noted with NT3 (Grundy et al., 2001).
Both cortisol and BDNF exhibit age-dependent changes that
may impact their role with damage and recovery after TBI,
especially as older age increases risk for mortality after TBI
(Roozenbeek et al., 2012). Positive correlations between high
cortisol levels and older age are likely due to age-associated HPA
axis changes, including decreased cortisol clearance and impaired
glucocorticoid negative feedback (Ferrari et al., 2001; Pal et al.,
2014). Older age is also linked to lower BDNF levels (Erickson
et al., 2012) and relative brain increases in the pro-apoptotic p75
receptor (Webster et al., 2006; Tapia-Arancibia et al., 2008). In
populations with TBI, both cortisol and BDNF levels vary by
age (Santarsieri et al., 2014; Failla et al., 2016), and our previous
work characterizes interactions between BDNF gene variation
and age that predict mortality post-TBI, wherein risk variants at
a particular gene locus differ by age (Failla et al., 2016).
The, BDNF genotypes (Val/Val) for rs6265 causes an amino-
acid substitution of valine to methionine at amino-acid residue
66 (Val66Met) (Tapia-Arancibia et al., 2004). This substitution
alters intracellular trafficking and packaging of pro-BDNF and
secretion of the mature peptide (Egan et al., 2003). Also,
rs7124442 (T/T homozygotes) are associated with activity
dependent BDNF secretion and BDNF mRNA trafficking (Egan
et al., 2003; Orefice et al., 2013). In our previous work (Failla et al.,
2015), a gene risk score (GRS) was used, ranking genetic variants
associated with decreased BDNF production or secretion, as
risk variants for mortality after TBI. These high risk genotypes
were associated with increased mortality only among younger
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individuals with TBI (age <45 years). However, for the low-
risk genotype there was an interaction by age, wherein younger
individuals with low-risk variants (high secretion/trafficking)
were protected against mortality, while older individuals with
low-risk variants were at an increased risk for mortality after TBI.
The literature evaluating cortisol actions in acute TBI
pathophysiology among clinical populations are limited. Our
previous work demonstrates that serum cortisol levels are
elevated over the first week after severe TBI, particularly among
older individuals, as a physiological response to the acute stress
of associated with severe injury and associated critical illness
(Wagner et al., 2011a). Although, some develop acute adrenal
insufficiency and a relative state of hypocortisolemia after injury
(Wagner et al., 2011a). In contrast, our previous work also shows
that acute CSF cortisol profiles are∼8–10X that observed among
healthy controls over the first week after severe TBI. Further,
persistent high acute CSF cortisol levels are associated both
increased mortality as well as worse survivor based outcomes
(Santarsieri et al., 2014). To date there are no clinical studies
delineating possible regulatory effects cortisol may have on
BDNF in the context of TBI.
Given the regulatory relationships between CORT and BDNF,
and their known individual relationships to TBI outcome,
we hypothesized that CSF cortisol would mediate CSF BDNF
associations with 6-month mortality in a model that also
considered age and BDNF genetics (e.g., as covariates or as
points of cohort stratification). We also hypothesized that BDNF
genetics would moderate the relationship between CSF BDNF
and cortisol trajectories. Our results confirm these hypotheses
and showed that CSF BDNF predicts, and BDNFGRSmoderates,
patient cortisol group-based trajectory analysis (TRAJ) group
membership. Also, cortisol TRAJ predicted 6-month mortality.
In mediation analysis, BDNF predicted mortality, with cortisol
acting as the mediator, and CSF cortisol mediation effects were
stronger among younger individuals (age <48 years) compared
to older individuals. Together, the findings suggest a possible
regulatory role for cortisol with BDNF’s contribution to TBI
pathophysiology and mortality, particularly among younger
individuals with severe TBI.
MATERIALS AND METHODS
Participants
This study was approved by the University of Pittsburgh
Institutional Review Board, and this cohort represents a subset
of patients enrolled in a larger study examining biomarker
and genetic relationships to outcome after TBI. Participants
were 16–73 years old and had a diagnosis of severe TBI
[GCS≤8, with positive findings consistent with TBI on CT
scan]. Self-reported non-White individuals were excluded as
BDNF levels and genetics vary based on race (Freedman et al.,
2004; Nettiksimmons et al., 2014). As shown in Figure 1, 216
participants had either BDNF or acute cortisol measurements;
specifically, 185 had BDNF and 155 had cortisol. There were
131 participants with both BDNF and cortisol. Fourteen were
excluded due to missing BDNF genotyping, GCS or mortality
data. The final sample size was 117 participants with TBI. CSF
FIGURE 1 | Diagram depicting how the cohort was derived for analysis.
The cohort was restricted to self-reported White individuals with complete
demographic, clinical, genetics and biomarker data. There were a total of 216
White severe TBI subjects with CSF Cortisol and BDNF. Of these, 185 and 155
subjects had CSF BDNF and cortisol, respectively. A total of 131 subjects had
both CSF cortisol and BDNF. A total of 14 subjects were removed for missing
BDNF genetics or GCS or mortality data, leaving a final cohort of 117.
1Used for estimating prior distributions in the mediation analysis path for
BDNF-mortality (total effect).
2Used for estimating prior distributions in the mediation analysis path of
BDNF-cortisol, cortisol-mortality, and BDNF-mortality (direct effect).
3Used to generate CSF cortisol trajectories in the most inclusive cohort with
CSF cortisol.
from 13 healthy subjects was obtained and used to generate a
control reference level for cortisol.
CSF Sample Collection and Processing
Brain-derived neurotropic factor (BDNF) and Cortisol were
measured from CSF samples collected the first week post-
injury. Samples were collected up to twice daily via EVD
(extraventricular drainage) catheter placed for routine clinical
care. For our injury cohort, 455 CSF samples were analyzed for
BDNF, and 400 CSF samples were analyzed for cortisol. Healthy
control subjects (N = 13) had CSF collected via lumbar puncture
at ∼7 a.m. After collection, samples were stored at 4◦C until
processing. Samples were then centrifuged, aliquoted, and stored
at −80◦C until batch analysis. CSF BDNF levels were measured
via ELISA kit (RayBiotech), previously detailed (Failla et al.,
2016). The inter/intra-assay coefficient of variation (CV) was
<10% and <12%, respectively; assay sensitivity was 80 pg/mL.
CSF cortisol levels were measured in with solid-phase 125I
RIA, Coat-A-Count R© in vitro Diagnostic Test Kit (Siemens
Healthcare Diagnostics). Inter- and intra-assay CVs were <10%.
Samples with levels below the given range were assigned the
detection limit value, and samples with undetectable levels
were assigned values of 0.001 for analysis purposes. Additional
samples were measured with a commercial ELISA kit (1-3002,
Salimetrics) according to manufacturer instructions, with some
adaptation for CSF measurement. To avoid matrix effects and to
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fit within the range of the kit, a 1:4 sample dilution was used.
The inter-/intra-assay CV was <10% and <16%, respectively.
Validation experiments with CSF also showed excellent linearity
with serial dilution and recovery from spiking (90%–110%).
Additionally, we measured cortisol levels by ELISA in 20 CSF
samples previouslymeasured by RIA to determine the correlation
between the two measurement methods. A linear regression fit
the relationship between the measured concentrations by RIA
and ELISA. The ELISA results were then converted using this
equation (CRIA = 6.32+ 0.76 × CELISA) before pooling data for
analyses.
Mortality
Six-month mortality status was examined using survival
analysis. GOS scores were obtained by research-trained
neuropsychometrists blinded to genetic and biomarker
information. The Social Security Death Index (http://www.
genealogybank.com/gbnk/ssdi/) was utilized to determine
mortality status, and time post-injury until death.
Genotyping and SNP Selection
DNA was either isolated from blood using a simple salting
out procedure or from CSF using the Qiamp DNA extraction
protocol (Qiagen). Two BDNF SNPs were genotyped by TaqMan
allele discrimination assay using commercial Assay-on-Demand
reagents (Applied Biosystems Incorporated). Genotype data calls
from two individuals, blinded to all phenotype data, were
compared; discrepancies were settled by reviewing the raw
data and rerunning samples when necessary. Hardy-Weinberg
equilibrium was confirmed for all allele frequencies.
Brain derived neurotrophic factor (BDNF) rs6265 and
rs7124442 were selected based on previous data correlating these
SNPs tomortality. Both rs6265 and rs7124442 have been reported
as functional with a minor allele frequency of 38.9 and 39.1%,
respectively. Each SNP represents a different haplotype block
of BDNF covering variation corresponding to BDNF isoform
A (Failla et al., 2015). A risk allele count, GRS, was used as
previously published (Failla et al., 2015) with the hypothesized
risk alleles, for young individuals with TBI, being rs6265Met and
rs7124442 C carriers (Egan et al., 2003; Orefice et al., 2013). The
GRS is fundamentally based upon the idea that genetic risk is
cumulative. The cumulative GRS for the two identified BDNF
variants ranged from 0 to 2 and was calculated by summing
the number of risk alleles for these two SNPs. GRS = 0 was
considered the no risk group (Val/Val, T/T), GRS = 1 contained
carriers for one risk allele (Val/Val, C-carrier or T/T,Met-carrier),
and GRS = 2 included carriers of both risk alleles (Met-carrier,
C-carrier). This method for GRS formulation is consistent with
GRIPS (Genetic RIsk Prediction Studies) guidelines (Janssens
et al., 2011).
Statistical Analysis
Analysis was performed with SAS (Statistical Analysis Software)
version 9.4 and the SPSS (Statistical Package for Social Sciences)
version 23. Descriptive statistics included means, standard error
of the mean (SEM), and frequencies. Mean comparisons for CSF
biomarkers and continuous demographic and clinical variables
were assessed using the Mann-Whitney U-test. Associations
between categorical demographic and clinical variables by
survival status were conducted using the Chi-square test, or
Fisher’s exact test (if applicable). The daily levels for CSF BDNF
and cortisol were also graphically represented by survival status.
Weekly average for BDNF were calculated by survival status and
GRS.
Trajectory Analysis
To assess temporal (repeated measures) CSF cortisol profiles, we
applied TRAJ (Niyonkuru et al., 2013) as previously reported
(Santarsieri et al., 2014, 2015) to describe multiple longitudinal
patterns of change in order to identify distinct subgroups within
the population. For cortisol, TRAJ was conducted on natural
log transformed values from 7 time points (D0–D6 post-TBI).
Cortisol group TRAJ membership identified individuals with
“high” vs. “low” cortisol level over this time frame.
For BDNF levels, we initially applied TRAJ procedures and
found an unbalanced group membership (>85% participants
belonged to the “low” group), indicating poor discrimination
of participants into homogeneous subgroups for longitudinal
BDNF levels. Also, upon inspecting daily levels, we observed
stable BDNF concentrations over time; given the minimal
temporal variation, we characterized mean BDNF above/below
the 75th percentile for analysis.
A Bayesian Approach to Inform and
Internally Validate Mediation Model
Attrition in sample size was a concern as the primary analysis
was restricted to subjects with samples of BDNF, cortisol, BDNF
genetics, GCS, and age. To protect against a selection bias of
only using information from subjects with complete data, we
used prior knowledge of the BDNF/mortality association to
inform the current study analysis. Specifically, we applied the
Bayes estimation using Monte Carlo Markov Chain (MCMC)
method to assess primary relationships. The MCMC method,
a stochastic procedure that estimates parameters of interest
using random generated samples, can be used with Bayes
estimation (Hamra et al., 2013). Using the MCMC method,
we obtained exact parameter distributions of interest instead
of asymptotic normal distribution requiring a medium or large
sample size under maximum likelihood estimation. Final Bayes
estimates rested between the prior distribution and the current
effect size obtained from the study cohort for our mediation
analysis. The MCMC procedure incorporates re-sampling of
regions from prior distributions, to increase estimate precision
and validity.
Mediation and Regression Analyses
Mediation is used to test whether a factor is in the causal pathway
between an exposure of interest and a selected outcome. We
hypothesized that cortisol trajectory can mediate the relationship
between BDNF and mortality. To formally test the hypothesis,
we applied the Baron and Kenny method of mediation
analysis (Baron and Kenny, 1986). In this method, a series of
regression models were performed to adjust for other potential
confounders.
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To examine whether the association between acute CSF BDNF
levels and mortality was mediated by acute CSF cortisol levels,
we established if the following four criteria for mediation effects
were met: (1) BDNF levels were associated with mortality (total
effect); (2) BDNF levels were associated with cortisol levels; (3)
cortisol levels were associated with mortality after adjusting for
BDNF levels; and (4) the association between BDNF levels and
mortality was attenuated after adjusting for cortisol level (indirect
effect).
We performed logistic regression to evaluate the significance
of criteria 2, and generated Cox proportional hazard models to
evaluate the significance of criteria 1, 3, and 4. Time of follow-
up was computed from injury and death date or 180 days (6-
months) after injury, which represents the right censored time
point. Regression and mediation analyses were performed for the
entire population and after stratifying the population at the 75th
percentile for age. Cox proportional hazard models were adjusted
for binary 75th percentile age (<48 vs. ≥48 years old), GCS and
GRS.
To investigate the moderating effects of GRS on BDNF level
associations with cortisol TRAJ group, we performed a logistic
regression model, stratified by GRS group (0 vs. 1 vs. 2). A two-
way interaction term between BDNF level and GRS was created
and fit into each model to assess the statistical significance of
interactions.
The mediation percentage was calculated by considering
the natural logarithm (ln) of the odds (or hazard) ratios
(OR) with the following equation: Mediation percentage =
{[ln(ORTotalEffect) − ln(ORDirectEffect)]/ln(OR TotalEffect)}
∗100%.
Conceptually, the relationship between BDNF andmortality may
be mediated by cortisol TRAJ, but this effect typically does not
account for 100% of that relationship, and there may be other
unmeasured factors that also mediate the relationship to some
degree. The direct effect, corresponds to the effect of BDNF on
mortality, adjusting for cortisol TRAJ. That is, if the mortality
relationship through cortisol TRAJ is removed, the remaining
effect represents BDNF effects on mortality without adjustment
for cortisol TRAJ. The indirect effect, or the mediation effect, is
derived by subtracting the total effect from the direct effect.
RESULTS
Cohort Demographics
There were 117 individuals with TBI in the final analytic sample
(Figure 1). The clinical and demographics for the whole cohort,
and stratified by survival is provided in Table 1. The age range
for this cohort was 16–74, with the mean age 36 years old.
Most subjects were men (85.3%). The median GCS was 7.
The primary mechanisms of injury were automobile (52.2%)
and motorcycle accidents (24.3%). The mean non-head Injury
Severity Score was 13.26, while the average length of acute
hospital stay was 21.2 days. The most prevalent neurological
injury types were subarachnoid hemorrhage (SAH, 70.1%) and
subdural hematoma (SDH, 69.2%). Individuals with TBI that
were non-survivors were significantly older, had lower GCS
scores (more severe injuries), fall mechanism of injuries, shorter
length of stays, and were more likely to have contusions and less
likely to have DAI in CT scans (p = 0.05 for all comparisons).
No other demographic and clinical variables were significantly
different by survival status.
CSF Cortisol Trajectory Profile
Trajectory analysis identified two different TRAJ group profiles:
high and low CSF cortisol (Figure 2). CSF cortisol levels for the
high group were higher than the low group on days 1–6 post-
injury (p < 0.01 all comparisons). CSF cortisol levels in the
high group peaked on day 2 post-injury and then declined, while
levels for the low group were highest on day 1, followed by a
modest decrease in levels. Also highCSF cortisol TRAJ group was
associated with increased mortality (P = 0.001) when adjusting
for age (<48 vs. ≥ 48 years old), GCS, and GRS. In the high
cortisol TRAJ group, there were significant differences in CSF
cortisol levels over time, with significant differences noted for day
0 vs. days 1–6 (P = 0.012 all comparisons). In the low cortisol
TRAJ group, we observed a stably low level from day 0 to 6 with
a small spike from day 0 to day 1 and a subsequent decline. There
was no significant difference of average day 1–6 levels compared
with day 0 (P = 0.219).
Characterization of Cortisol and BDNF
Profiles by Survival Status
In Figure 3A, daily cortisol levels were graphed by survival
status. In days 2, 3, and 4, non-survivors had significantly
elevated cortisol levels compared to survivors (p < 0.05 all
comparisons). Daily levels of CSF BDNF were plotted by survival
status (Figure 3B). Levels were significantly elevated among non-
survivors compared to survivors at day 3 and 5 (p < 0.05).
There was a trend toward lower BDNF levels for non-survivors
compared to survivors at day 0 (p = 0.078). No other day was
significantly different with respect to BDNF levels by survival
status.
Cortisol Trajectory Mediates BDNF
Associations with Mortality
We obtained prior knowledge of the coefficient of each
corresponding pathway in the mediation analysis from our
original study cohort of all subjects with BDNF (n = 185).
The summary of the prior knowledge used is provided in
Table 2. Prior information showed those with a mean CSF BDNF
level ≥75th percentile were more often in the high cortisol TRAJ
group (HR = 4.12, 95% CI: 1.86, 9.24, P = 0.001), after adjusting
for age, GCS and GRS. Mediation analysis, adjusting for binary
age, GCS, and GRS, showed CSF BDNF levels dichotomized at
the 75th percentile were associated with mortality (total effect)
(HR = 1.94, 95% CI: 1.19, 3.12, P = 0.011). The CSF BDNF-
mortality association was attenuated after adjusting for CSF
cortisol TRAJ membership (direct effect) (P = 0.106), possibly
suggesting a full mediation of CSF BDNF-mortality association
through CSF cortisol. However, the proportion of mediation
was ∼30% (see Table 3); therefore, we report partial mediation
effects of CSF cortisol. The mediation effect was stronger among
younger individuals (≤48 years old) (mediation ∼45%) when
the population was stratified and evaluated in separate models
(Table 3). There were no significant mediation effects among
older individuals, although this group has a small sample size
(N = 27).
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TABLE 1 | Demographic and clinical characterization of the cohort.
Overall (n = 117) Survivors (n = 91) Non-survivors (n = 26) P-value
Age in years (mean ± SE) 36.0 ± 1.5 32.40 (1.4) 48.42 (3.7) <0.001*
Sex, Men (%) 99 (85.3) 77 (85.6) 22 (84.6) 0.905
GCS, median (IQR) 7 (6-7) 7 (6-8) 6 (6-7) 0.043*
Mechanism of injury, n (%) 0.034*
Automobile 60 (52.2) 41 (45.6) 7 (26.9)
Motorcycle 28 (24.3) 22 (24.4) 6 (23.1)
Fall/jump 19 (16.5) 10 (11.1) 9 (34.6)
Other 8 (7.0) 17 (18.9) 4 (15.4)
Length of hospital stay in days (mean ± SE) 21.2 ± 1.0 23.01 (1.1) 14.68 (1.7) 0.002*
Injury Severity Score Non-head (mean ± SE) 13.26 (1.0) 12.99 (1.0) 14.18 (2.3) 0.822
Neurological injury type, n (%)
SDH 81 (69.2) 60 (65.9) 21 (80.8) 0.148
DAI 36 (30.8) 33 (36.3) 3 (11.5) 0.016*
EDH 14 (12.0) 11 (12.1) 3 (11.5) 0.939
Contusion 52 (44.4) 35 (38.5) 17 (65.4) 0.015*
IVH 39 (33.3) 32 (35.2) 7 (30.0) 0.432
ICH 40 (34.2) 30 (33.0) 10 (38.5) 0.602
SAH 82 (70.1) 61 (67.0) 21 (80.8) 0.177
rs6265, n (%) 0.617
Val/Val 68 (58.1) 54 (59.3) 14 (53.9)
Met-carrier 49 (41.9) 37 (40.7) 12 (46.2)
rs7124442, n (%) 0.520
T/T 61 (52.1) 46 (50.6) 15 (57.7)
C-carrier 56 (47.9) 45 (49.5) 11 (42.3)
BDNF mean (SE) 0.19 (0.01) 0.18 (0.01) 0.21 (0.02) 0.045*
Cortisol mean (SE) 24.28 (1.3) 21.01 (1.20) 35.75 (3.45) <0.0001*
*p ≤ 0.05.
BDNF Biomarker Associations with
Cortisol Are Dependent upon BDNF
Genotype
We generated separate models among those with GRS = 0, GRS
= 1, and GRS = 2 to evaluate the predictive capacity of CSF
BDNF with regard to CSF cortisol TRAJ group membership.
These age-adjusted models showed that, among subjects with
GRS = 1, being in the high BDNF group (>75th percentile) was
associated with high CSF cortisol TRAJ group membership (OR
= 6.50, 95% CI: 1.70, 24.81, P = 0.006) (Table 4). In Figure 4,
average BDNF levels were calculated by GRS in each cortisol
TRAJ group. In GRS= 1 group, there is a significant difference in
BDNF levels in CORT TRAJ high vs. low (p = 0.011). There is no
statistically significant difference for GRS 0 or 2. These findings
are consistent with the results from Table 4, wherein the GRS =
2 group was relatively small in sample size.
BDNF Genetic Interactions with CSF BDNF
Level Mortality Relationships May Be Age
Dependent
An age stratified analysis, with separate models for age <48 vs.
≥48 years old, revealed younger individuals had a significant
CSF BDNF∗GRS interaction in this mortality model (Table 5,
P = 0.028). This model was adjusted for GCS and cortisol TRAJ
group. For younger people, this interaction shows the association
between high BDNF andmortality varies by BDNF genotype such
that those with higher secretion genotypes (GRS = 0) have a
higher mortality risk.
In Figure 5A, average BDNF levels were calculated by survival
status and GRS. In non-survivors, there is a significant difference
in mean BDNF levels by GRS (p = 0.015), such that individuals
with GRS of 2 had the lowest BDNF levels and individuals with
GRS of 0 had the highest BDNF. Also, non-survivors with a GRS
of 0 had significantly increased BDNF compared to survivors
with a GRS of 0 (p = 0.007). In Figure 5B, BDNF levels by
survival status and GRS were calculated among just individuals
<48 years old. In non-survivors, there was a significant difference
in BDNF levels by GRS, with individuals with GRS of 2 having
the lowest BDNF (p = 0.032). Among individuals with GRS of
0, BDNF levels were significantly elevated among non-survivors
compared to survivors (p = 0.015). There were no significant
differences in BDNF levels by GRS among either survivors or
non-survivors over the age of 48 (data not shown). Together,
these data are consistent with the multivariate model in Table 5
and suggest CSF cortisol has a regulatory influence on younger
individuals with high BDNF levels and a low BDNF secretion
genotype.
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FIGURE 2 | Daily mean CSF cortisol levels for CSF cortisol TRAJ groups (N = 117). Daily mean CSF cortisol levels for the cortisol TRAJ groups. Error bars
indicate standard error of the mean. There was a significant difference in CSF cortisol levels between the two groups on days 1–6 (p < 0.01). CSF cortisol values are
provided for N = 13 healthy controls as a reference.
DISCUSSION
Cortisol and BDNF are crucial biomarkers to characterize in
the context of TBI, as they can have both potentially useful
and harmful effects in the brain. This study investigated the
relationship between CSF cortisol and BDNF as gene- and
age-dependent biomarkers that predict mortality after TBI.
We found cortisol mediates BDNF effects on mortality after
TBI and that genetics and age also influence this mediation
effect. While our previous work shows cortisol and BDNF are
predictive biomarkers for outcome post-TBI (Santarsieri et al.,
2014; Failla et al., 2016), no studies have investigated the inter-
relationships between these biomarkers, and their combined
effects on clinical outcome. These data show the direct effects
of high BDNF levels on mortality are more pronounced among
younger individuals with TBI who also have high secretion BDNF
genotypes. However, the regulatory (mediating) effects of high
CSF cortisol on BDNF mortality risk occurs among those with
low BDNF secretion genotypes.
We also found increased cortisol levels are associated with
mortality after TBI. Elevated CSF cortisol is linked to an increased
inflammatory response among adults with severe TBI (Santarsieri
et al., 2015). While traditionally considered as having anti-
inflammatory properties (Barnes, 1979), recent work suggests
under certain conditions, CNS cortisol creates a more permissive,
pro-inflammatory state (Sapolsky et al., 2000; Yeager et al., 2004).
In addition to inflammation, cortisol has signaling and regulatory
influences on neurotrophins (McEwan, 2012), particularly BDNF
(Rothman and Mattson, 2013).
A prolonged, elevated cortisol state, which occurs with
ongoing stress and is further perpetuated by impaired negative
feedback secondary to the stress response, can result in reduced
synaptic plasticity, mediated by glucocorticoid downregulation of
BDNF expression (Duman et al., 1997; Numakawa et al., 2009).
The focus on BDNF effects on learning andmemory has garnered
significant attention for BDNF due to its role in plasticity
and neural maintenance, but BDNF is a viable biomarker for
mortality as first reported by Failla et al. (2015).
Many studies have shown an inverse relationship between
cortisol and BDNF in the setting of chronic stress and in
experiments with glucocorticoid injections, where elevated
cortisol leads to BDNF reductions (Smith et al., 1995) and
adrenalectomy results in elevated BDNF levels (Stranahan et al.,
2011). Our current study found positive associations between
elevated CSF cortisol and BDNF levels. A closer, temporal
examination of the stress literature demonstrates that acute stress
increases BDNF (Marmigère et al., 2003; Tapia-Arancibia et al.,
2004), while chronic stress reduces BDNF (Smith et al., 1995;
Liston and Gan, 2011). This acute increase in BDNF has been
confirmed in experimental TBI models across multiple brain
regions (Yang et al., 1996; Hicks et al., 1997; Grundy et al., 2000;
Rostami et al., 2014), while regional reductions in BDNF have
also been documented at chronic time points after experimental
TBI (Chen et al., 2005).
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FIGURE 3 | (A) Acute CSF Cortisol by Survival Status (N = 117). The open circles indicate survivors and closed circles are non-survivors. Data for CSF Cortisol
(ng/mL) were averaged within survival category each day. Error bars indicate standard error of the mean. On days 2–4, CSF Cortisol levels were significantly (p < 0.05)
elevated among non-survivors compared to survivors. (B) Acute CSF BDNF by Survival Status (N = 117). The open circles indicate survivors and closed circles are
non-survivors. Data for CSF BDNF (ng/mL) were averaged within survival category each day. Error bars indicate standard error of the mean. On days 3 and 5, CSF
BDNF levels were significantly (p < 0.05) elevated among non-survivors compared to survivors. There was a trend toward significant difference in levels on day 0
(p = 0.078); there were no significant differences in CSF BDNF levels for any other day.
This initial increase in BDNF may represent a physiological
response to influence HPA reactivity and attempt to maintain
homeostasis within the brain in response to initial/acute
stress (Marmigère et al., 2003; McEwan, 2015). However,
BDNF increases can be pathological in the setting of high
and/or prolonged pathophysiological stress (e.g., TBI). Clinically,
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TABLE 2 | Prior knowledge of BDNF and mortality association mediated by cortisol level among all subjects and stratified by 75th quartile of age.
All subjects (N = 185) Age ≤ 48 years (N = 139) Age >48 years (N = 46)
Pathwaya β (SE) P-value β (SE) P-value β (SE) P-value
BDNF to Cortisol (Logistic)b 1.35 (0.48) 0.005 1.94 (0.61) 0.001 0.30 (0.75) 0.694
Cortisol to mortality (Cox) 1.13 (0.40) 0.005 1.00 (0.56) 0.095 1.27 (0.57) 0.026
BDNF to mortality-Total Effect (Cox) 0.65 (0.30) 0.033 1.03 (0.42) 0.015 0.30 (0.41) 0.457
BDNF to mortality-Direct Effect (Cox)c 0.47 (0.38) 0.217 0.54 (0.65) 0.407 0.48 (0.49) 0.324
aAll pathways adjusted for 75th percentile age (at 48 year old).
bWeekly average CSF BDNF in ng/mL (≥75th percentile, <75th percentile); CSF cortisol using trajectory analysis grouping (low vs. high).
cAlso adjusted for cortisol trajectory grouping (low vs. high).
Bolded p-values indicate statistical significance.
TABLE 3 | Bayes estimation of BDNF and mortality association mediated by cortisol level among all subjects and by 75th percentile of age using Monte
Carlo Markov Chain (MCMC) methoda.
All subjects (N = 117) Age ≤ 48 years (N = 90) Age >48 years (N = 27)
Pathwayb HR/OR (95% CI) P-value HR/OR (95% CI) P-value HR/OR (95% CI) P-value
BDNF to Cortisol (Logistic) 4.12 (1.86–9.24) 0.001 7.48 (3.22–17.92) <0.001 1.44 (0.43–4.80) 0.185
Cortisol to mortality (Cox) 3.05 (1.70–5.45) <0.001 2.99 (1.27–7.00) 0.017 3.61 (1.53–8.97) 0.006
BDNF to mortality-Total Effect (Cox) 1.94 (1.19–3.12) 0.011 2.89 (1.42–5.70) 0.004 1.47 (0.73–2.95) 0.221
BDNF to mortality-Direct Effect (Cox) 1.58 (0.90–2.78) 0.106 1.78 (0.72–4.42) 0.185 1.72 (0.78–3.76) 0.159
Mediation percentage (95% CI)c 29.92% 45.45% −41.10%
(19.58–40.25%) (34.05–56.85%) (−93.52%, 11.33%)
aAnalysis was performed with weekly average CSF BDNF in ng/mL (≥75th percentile, <75th percentile); cortisol using trajectory analysis grouping (low vs. high); Prior distribution of
coefficients for each corresponding pathway (Table 2) was incorporated in MCMC Bayes estimation, which resamples prior distributions to derive a more precise and valid parameter
estimate.
bAll pathways were adjusted for 75th percentile age (<48 vs. ≥48 years old), Glasgow Coma Scale (GCS) and Gene Risk Score (GRS). For “BDNF to mortality-Direct Effect,” cortisol
using trajectory analysis grouping (low vs. high) was additionally adjusted.
cThe mediation percentage was calculated with the following equation: Mediation percentage = {[ln(ORTotal Effect ) − ln(ORDirect Effect )]/ln(OR Total Effect)}*100.
Bolded p-values indicate statistical significance.
TABLE 4 | Odds Ratios and 95% Confidence Intervals for CSF BDNF and cortisol levels.
GRS = 0 (N = 29)a GRS = 1 (N = 71) GRS = 2 (N = 17)
Cortisol TRAJ
Group 2 vs. 1b
OR (95% CI)c Cortisol TRAJ
Group 2 vs. 1b
OR (95% CI) Cortisol TRAJ
Group 2 vs. 1b
OR (95% CI)
BDNF 75th pct. 15/14 2.46 (0.30, 16.13) 23/48 6.50 (1.70, 24.81) 6/11 9.00 (0.28, 285.51)
P trend 0.285 0.006 0.213
Individual Models stratified by Gene Risk Scores.
aGRS score: 0 = Val/Val (rs6265) and T/T (rs7124442); 1 = Val/Val (rs6265), C-carriers (rs7124442) or Met-Carriers (rs6265), T/T (rs7124442); 2 = Met-Carriers (rs6265) and C-Carriers
(rs7124442).
bNumber of subjects in each cortisol trajectory group (Group 2 has higher cortisol level).
cAdjusted for binary age (≤48 vs. >48 years old).
Bolded p-value indicates statistical significance.
increased CSF BDNF may be due to BBB disruption after TBI.
In addition to brain production, BDNF is synthesized in the
periphery (Caporali and Emanueli, 2009) and can be stored
and released from platelets (Nakahashi et al., 2000) after tissue
injury (Fujimura et al., 2002). Failla et al. (2015) demonstrated
that serum BDNF levels are reduced post-TBI, hypothesizing
that reduced serum levels may be due BDNF transit into the
CNS, resulting in an acute increase in CSF BDNF. In either
case, increased CSF BDNF may represent failed compensatory
mechanisms that result in higher risk for mortality.
Acutely elevated CSF BDNF levels may not represent
neuroprotective processes due to injury induced regional
changes in TrkB vs. p75 target receptor expression. BDNF
is released as proBDNF, which binds to the pro-apoptotic
p75NTR. When cleaved by plasmin producing mature BDNF, this
molecule binds to the pro-survival TrkB receptor. Experimental
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FIGURE 4 | Acute CSF BDNF by Cortisol Trajectory Group by GRS. Weekly average CSF BDNF (ng/mL) is reported. Error bars indicate standard error of the
mean. White, gray, and black corresponds to GRS scores of 0, 1, and 2, respectively. Results are stratified among the high (n = 44) and low (n = 73) cortisol TRAJ
groups. Among individuals with GRS = 1, those in the high cortisol TRAJ group had significantly elevated BDNF levels compared to those in the low cortisol TRAJ
group p = 0.011. There were no significant differences in BDNF levels by cortisol TRAJ group for individuals with GRS of 0 or 2.
TABLE 5 | Cox proportional hazards model for the association between
BDNF and mortalitya.
Age below 75th
percentile (≤48 years)
(N = 90)
Age above 75th
percentile (>48 years)
(N = 27)
Coefficient (SE) P-value Coefficient (SE) P-value
BDNF*GRS −2.28 (1.04) 0.028 −0.26 (1.13) 0.819
Individual models are stratified by age.
aCovariates included in the model: GCS, cortisol (trajectory group).
Bolded p-value indicates statistical significance.
excitotoxic conditions, characteristic of TBI, have demonstrated a
downregulation of full-length tyrosine kinase receptor (TrkB.FL)
and an upregulation of the inactive truncated form of the receptor
(TrkB.T) (Gomes et al., 2012; Vidaurre et al., 2012). A regionally
specific increase in p75NTR receptors additionally contributes
to a shift from pro-survival to pro-apoptotic BDNF function,
possibly contributing to increased mortality after injury. Aging
also can detrimentally shift the BDNF receptor ratios, along
with causing regional reductions in BDNF and TrkB mRNA
expression (Romanczyk et al., 2002; Webster et al., 2006),
including in the hypothalamus (Tapia-Arancibia et al., 2004).
This age-related decline in BDNF pro-survival signaling may
possibly hinder neuronal survival and maintenance, therefore
increasing mortality risk. Age, and possibly also injury, related
increases in p75NTR receptors may contribute to less apparent
cortisol mediation effects on BDNF associations with mortality.
Cortisol mediation of BDNF effects on mortality may be more
prominent among those with high BDNF levels and concurrent
low BDNF secretion genotypes, and the reportedmediation effect
suggest that there may be a mechanism connecting these two
signaling pathways in the context of TBI mortality. One plausible
mechanism might involve post-TBI cortisol elevations inhibiting
the interaction of Shp2 with TrkB, affecting neurological injury
severity. Cortisol mediated inhibition of this signaling pathway
suppresses the MAPK/ERK pathway (Kumamaru et al., 2011),
essential for transcribing certain neural plasticity genes (Arango-
Lievano et al., 2015). Disrupted TrkB signaling could increase
brain tissue damage even while elevated glucocorticoid levels
are simultaneously increasing pro-BDNF and tissue plasminogen
activator expression (Revest et al., 2014), to generate mature
BDNF.
Another possible mechanism for cortisol mediated BDNF
mortality effects is through autonomic instability after injury.
TBI results in a marked disruption in autonomic balance and
stability. Evidence of reduced HRV after TBI implies reduced
parasympathetic tone (Baguley et al., 2006). With TBI, HRV
has been shown to predict brain death and cerebrovascular
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FIGURE 5 | (A) Acute CSF BDNF by Mortality Status by GRS. Weekly average CSF BDNF (ng/mL) is reported. Error bars indicate standard error of the mean. White,
gray, and black corresponds to GRS scores of 0, 1, and 2, respectively. Results are stratified among survivors (n = 91) and non-survivors (n = 26). Among
non-survivors, there is a significant difference in BDNF levels by GRS, such that higher GRS scores have lowest BDNF levels (p = 0.015). There is no difference in
BDNF levels by GRS in survivors-only. Only among individuals with GRS scores of 0 is there a significant difference in BDNF levels in survivors compared to
non-survivors (p = 0.007). (B) Acute CSF BDNF by Mortality Status by GRS among age below 48. Weekly average CSF BDNF (ng/mL) in reported after restricting
population to only individuals below age 48. Error bars indicate standard error of the mean. White, gray, and black corresponds to GRS scores of 0, 1, and 2,
(Continued)
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FIGURE 5 | Continued
respectively. Results are stratified among survivors (n = 78) and non-survivors (n = 12). Among non-survivors, there is a significant difference in BDNF levels by GRS,
such that higher GRS scores have lowest BDNF levels (p = 0.032). There is no difference in BDNF levels by GRS in survivors-only. Only among individuals with GRS
scores of 0 is there a significant difference in BDNF levels in survivors compared to non-survivors (p = 0.015).
FIGURE 6 | Conceptual figure capturing biomarker relationships among younger individuals (≤48 years. Old, N = 90): (1) cortisol has a significant
regulatory (mediating) effect on BDNF’s influence on mortality, accounting for ∼45% of BDNF’s mortality effects; (2) the association between BDNF above/below the
75th percentile and high cortisol TRAJ is only significant among individuals with low BDNF secretion genotypes; and (3) the direct association between BDNF
above/below the 75th percentile and mortality risk is stronger among individuals with the high BDNF secretion genotype (GRS = 0) compared to the low secretion
genotypes. Taken together, the data support a conceptual model for younger individuals with TBI wherein high BDNF levels among those with high BDNF secretion
phenotypes directly increases mortality risk, while mortality risk for those with high BDNF levels paired with low BDNF secretion genotypes is regulated (mediated) by
cortisol.
dysregulation (Ryan et al., 2011), and HRV is associated with
autonomic dysfunction in multiple other pathological states
including sepsis, shock, and adrenal insufficiency (Morris et al.,
2007; Werdan et al., 2009), each of which can co-occur in TBI.
Further work suggests that HRV can be an effective mortality
predictor, among hemodynamically stable patients with TBI
(Ryan et al., 2011). Importantly, there is evidence that BDNF
levels (Pal et al., 2014), BDNF genetic variability (Yang et al.,
2010), and cortisol levels (Pal et al., 2014) are associated with
HRV, making autonomic instability a plausible mechanism by
which cortisol regulation of BDNF affects mortality risk.
Our previous work defined “risk alleles” as the genetic
variations of the BDNF SNPs rs6265 and rs7124442 that result in
lower activity-dependent BDNF secretion and impaired BDNF
mRNA trafficking, respectively (Egan et al., 2003; Orefice et al.,
2013), to create a GRS (Failla et al., 2015). Interestingly, higher
GRSs were only associated with BDNF related mortality among
younger subjects. A more nuanced look at the relationship
between cortisol and BDNF in our population showed very
high BDNF levels are associated with high cortisol levels among
people who have a low secretion “risk allele” (rs6265 Met or
rs7124442 C). Among these individuals, high CSF BDNF levels
were associated with high CSF CORT TRAJ group membership.
Our previous work suggests these risk variants are associated
with lower serum BDNF. Previous work elaborated that, in
addition to lower BDNF secretion capacity and autonomic
mediated suppression of serum BDNF, low serum BDNF post-
TBI may be due to reactive platelet BDNF dumping systemically
and more BBB BDNF transit into the CNS (Tanno et al.,
1992; Failla et al., 2016). Taken together, cortisol may have a
regulatory influence (i.e., mediation effect) under conditions
where innate BDNF production capacity is reduced, yet CNS
BDNF levels are high due to injury severity factors, such as
cortisol induced suppression of Shp2 associated MAPK/ERK
signaling, reactive platelet dumping of BDNF systemically, and
increased serum-to-CSF BBB transit. Our work is consistent with
previous studies where those with rs6265Met/Met homozygosity
possessed significantly higher HPA axis reactivity, determined by
serum cortisol elevations in response to physical stress (Schüle
et al., 2006).
Our study demonstrates age contributes to biomarker
associations on outcome after TBI. Age can affect many different
biomarkers, including stress hormones (Wagner et al., 2011a;
Santarsieri et al., 2014; Ranganathan et al., 2016), sex hormones
(Ranganathan et al., 2016), inflammation (Kumar et al., 2016),
and BDNF (Failla et al., 2015). Experimental models show
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decreased BDNF mRNA, BDNF protein, and TrkB.FL mRNA in
many different brain regions with older age (Romanczyk et al.,
2002; Webster et al., 2006; Erickson et al., 2012). Our study
demonstrated that in younger subjects (age < 48 year), CSF
BDNF effects on mortality can differ as a function of genetic
variation, while this BDNF∗GRS interaction is not significant
among older subjects. Lower sample size for the older subgroup,
and for the GRS = 2 subgroup, are potential alternative reasons
for this finding.While specificmechanisms are difficult to discern
with these clinical biomarker data, age related differences in
BDNF secretion capacity (perhaps due to age-dependent risk
factors like hypertension, cerebral hypoperfusion, and poor
glucose metabolism) (Kennedy et al., 2009; Erickson et al., 2012),
age related increases in CSF BDNF acutely (Failla et al., 2015), and
also target receptor milieu (Erickson et al., 2012) may contribute
to this finding. What the data do suggest though is that, in the
context of TBI, factors other than genetics contribute to CSF
BDNF profiles observed in this age group.
While BDNF secretion capacity is reduced with aging, CSF
BDNF levels are elevated after TBI and are increased with age
(Failla et al., 2015). Although CSF cortisol relationships to CSF
BDNF were studied, both BDNF and cortisol are synthesized in
the periphery and likely contribute to the CSF profiles observed.
Notably, BDNF levels are reduced in serum after TBI and
are associated with mortality (Failla et al., 2015), while serum
cortisol profiles are not associated with mortality (Wagner et al.,
2011a). Thus, it is unclear at this point, how serum relationships
between BDNF and cortisol might differ from CSF relationships
between these two markers and why. Presumably, variable levels
of BBB dysfunction, acute adrenal insufficiency associated with
the critical illness that accompanies severe TBI, and personal
biology may influence these relationships, creating the possibility
for potentially heterogeneous or dynamic relationships with the
role that CSF cortisol plays in the causal pathway between CSF
BDNF and mortality.
The study has several limitations, including small sample
size, particularly for age stratified analyses and for the BDNF
cut-point. Dividing the age groups at the 75th percentile left
the model underpowered to fully explore GRS∗CSF BDNF
interactions in the older age group, and larger future studies
focusing on this older population would be beneficial. We used a
data driven approach to determine the 75th percentile as the cut
point for BDNF analyses. Specifically, the 75th percentile cutoff
was based on our preliminary analysis where we used a larger, and
presumablymore representative cohort, to define the cut-point to
be used with the Bayesian model. We believe the 75th percentile
is a good starting estimate for examining high BDNF levels in
other populations. It is possible that the actual cut point may vary
in other populations (70th, 80th, percentile, etc.). However, our
main interpretation of this work is that cortisol levels mediate
associations between high BDNF levels and mortality.
Due to effects of race on BDNF allelic frequencies, we limited
our analyses to self-reported Whites. Also, the group with a
GRS = 2 is small, making significant associations with cortisol
TRAJ challenging despite the large odds ratio. Despite this,
some issues with low sample size are overcome by using the
MCMCmethod of Bayes estimation, which uses prior knowledge
to inform a posterior probability based on the current study
data; it also incorporates a validation process to internally re-
sample prior distributions to arrive at more precise and valid
parameters. Future studies could consider a weighted GRS
score formulation to better quantify the relative contribution
each variant contributes to genetic associations identified in
this study. Additionally, our small sample size limited our
ability to differentiate BDNF heterozygote gene effects from
variant homozygote gene effects on mortality. Examining BDNF
heterozygote gene effects, including unique interactions with
cortisol, may be relevant to TBI pathophysiology (Kim et al.,
2011; Notaras et al., 2016).
Including only self-reported whites is an additional limitation
as the results may not be generalizable to other races. However,
the literature is clear that racial genetic differences can confound
the relationships assessed (Freedman et al., 2004; Nettiksimmons
et al., 2014). Only two BDNF gene variants were used to construct
the GRS, which likely underestimates the total variance explained
by BDNF genetics on cortisol profiles, BDNF profiles, and
mortality; nevertheless, the chosen variants are both functional
and affect BDNF (Egan et al., 2003; Orefice et al., 2013) and
cortisol (Alexander et al., 2010; Armbruster et al., 2016) levels
clinically. Additionally, our BDNF ELISA does not differentiate
between the proBDNF and mature BDNF isoforms.
Despite these limitations, this study suggests causal effects
of cortisol on mortality for those with high BDNF that are
more pronounced among younger individuals with low
BDNF secretion genotypes. While this causal relationship
is important for mortality prediction post-TBI, specific
mechanisms facilitating this relationship have yet to be
discerned; additionally the high BDNF secretion genotype
directly increases mortality risk among younger individuals
with high BDNF levels (see Figure 6). In addition to injury
effects on both CSF BDNF and cortisol biomarker levels (e.g.,
BBB damage), mechanisms by which these biomarkers interact
with each other, age, and genetics to impact mortality are likely
varied, but may reflect both neurological injury severity and
autonomic instability. Future experimentation should evaluate
how our mediation effects translate mechanistically to brain
tissue BDNF and BDNF target receptor signaling after TBI.
Additional trauma to body regions outside the head is common
in the population with severe TBI. These injuries, as well as other
systemic complications, such as hospital acquired pneumonia,
sepsis, and shock can be non-neurological contributors to
mortality. Thus, future work considering if/how serum BDNF
or Cortisol reflect the peripheral injury response, and its effects
on TBI pathophysiology is warranted. Clinically, it would be
interesting to further characterize BDNF cortisol relationships,
with survivor based outcomes, like learning and memory,
from the viewpoint of post-acute TBI serving as a chronic
stress paradigm influencing regulatory relationships between
cortisol and BDNF. Understanding these dynamic relationships
of secondary injury occurring after TBI may facilitate more
effective, personalized interventions after injury.
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